Abstract:Objective To evaluate therapeutic effect of the sphingosine-1-phosphate receptor antagonist FTY720 on the imiquimod-induced psoriasis-like mouse model,and to explore its molecular mechanism.Methods A total of 8 specific pathogen-free (SPF) female C57BL/6 mice were used in this study,and divided into experimental group (n =3) and control group(n =5):each mouse ear was topically treated with 10 mg/d imiquimod for 7 consecutive days,and the experimental group and control group were intraperitoneally injected with FTY720 and phosphate buffer saline (PBS) respectively on days 2,4 and 6.Ear skin thickness was measured every day.These mice were sacrificed on day 8,and histopathological changes of the ear skin were observed.The ear tissues and draining cervical lymph node cells were obtained.Flow cytometry was performed to analyze changes in the proportion of interleukin (IL)-17+ γδT cells in the mouse skin and draining lymph node tissues between the two above groups,and to determine the expression of sphingosine-1-phosphate receptor 1 (S 1P 1) and cutaneous lymphocyte antigen (CLA) on the surface of the γδT cells.The means of two independent samples were compared by using t test.Results After the 2-day topical application of imiquimod,the mouse ear thickness was significantly lower in the experimental group (0.217 mm± 0.003 mm) than in the control group (0.232 mm ± 0.002 mm,t =4.23,P ＜ 0.01) on day 3,and the significant difference existed till day 8 (all P ＜ 0.01).Histopathological examination of the ear skin revealed that the epidermal thickness was significantly lower in the experimental group (18.62 μm ± 0.19 μm) than in the control group (27.79 μm ± 1.58 μm,t =4.35,P ＜ 0.01).Immunofluorescence staining showed that the degree of neutrophil infiltration in the mouse ear tissue was lower in the experimental group than in the control group.As flow cytometry showed,the proportion of neutrophils was significantly lower in the experimental group (1.57％ ± 0.12％) than in the control group (3.03％ ± 0.33％,t =3.31,P =0.016).In the ear tissues,the experimental group showed significantly decreased proportion of γδT cells or IL-17+ γδT cells (4.88％ ± 0.42％,40.53％ ± 1.76％ respectively) compared with the control group (9.45％ ± 1.22％,56.56％ ± 0.66％ respectively;t =2.75,10.27 respectively,both P ＜ 0.05).In the draining lymph nodes,the experimental group showed significantly increased proportion of γδT cells or IL-17+ γδT cells compared with the control group (t =5.781,4.140 respectively,both P ＜ 0.05),and the fluorescence intensity of S1P1 and CLA in the γδT cells was significantly lower in the experimental group than in the control group (P ＜ 0.05).Conclusion FTY720 can alleviate imiquimod-induced psoriasis-like manifestations in mouse models,likely by down-regulating the expression of S1P1 and CLA in γδT cells,increasing the proportion of γδT cells in the draining lymph nodes followed by the decrease of their proportion in the skin,and decreasing the production of IL-17 in skin tissues.

Ameliorative Effects of a Fusion Protein Dual Targeting Interleukin 17A and Tumor Necrosis Factor Α on Imiquimod-Induced Psoriasis in Mice.

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

L-Theanine Alleviates IMQ-Induced Psoriasis Like Skin Inflammation by Downregulating the Production of IL-23 and Chemokines

A Novel Fusion Protein Attenuates Collagen-Induced Arthritis by Targeting Interleukin 17A and Tumor Necrosis Factor Alpha

Deucravacitinib and shikonin combination therapy ameliorates imiquimod-induced psoriasis in mice

Topical anti-TNF-a ssDNA aptamer decreased the imiquimod induced psoriatic inflammation in BALB/c mice

Tetrastigma hemsleyanum polysaccharides alleviate imiquimod-induced psoriasis-like skin lesions in mice by modulating the JAK/STAT3 signaling pathway

Effect of the sphingosine-1-phosphate receptor antagonist FTY720 on γδT cells in the skin of imiquimod-induced psoriasis-like mouse model

NOVEL EVALUATIONS OF PROTOCATECHUIC ACID TO TARGET IL-17A FOR PSORIASIS PROTECTION IN MICE

Diosmetin ameliorates imiquimod-induced psoriasis by regulating apoptosis and inflammation via toll-like receptor 4/nuclear factor kappa B pathway

Terrestrosin D ameliorates skin lesions in an imiquimod-induced psoriasis-like murine model by inhibiting the interaction between Substance P and Dendritic cells

KdPT Alleviates Imiquimod-Induced Psoriasis-Like Skin Lesion in Mice Via Inhibiting Proliferation and Inflammation Response.

Tiamulin Inhibits TNF-α and Alleviates Psoriasis-Like Dermatitis.

Quercetin Ameliorates Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Via the NF-κB Pathway.

Human IL-23R Cytokine-Binding Homology Region-Fc Fusion Protein Ameliorates Psoriasis via the Decrease of Systemic Th17 and ILC3 Cell Responses

Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17

Thymopentapeptide Affects T-Cell Subsets by Modulating the Flora of the Skin Surface to Alleviate Psoriasis

LY294002 ameliorates psoriatic skin inflammation in mice via blocking the Notch1/Hes1-PTEN/AKT/IL-17A feedback loop

Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.

Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice

Topical application of imatinib mesylate ameliorated psoriasis‐like skin lesions in imiquimod‐induced murine model via angiogenesis inhibition